[HTML][HTML] Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly, C Roth… - Iscience, 2023 - cell.com
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly, C Roth… - iScience, 2023 - hal.univ-smb.fr
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
[PDF][PDF] Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, L Bayry, A Gilardin - publications.iitpkd.ac.in
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
C Chauvin, L Levillayer, M Roumier, H Nielly, C Roth… - 2023 - cabidigitallibrary.org
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
[引用][C] Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly… - …, 2023 - ui.adsabs.harvard.edu
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential
against SARS-CoV-2 variants - NASA/ADS Now on home page ads icon ads Enable full ADS …
against SARS-CoV-2 variants - NASA/ADS Now on home page ads icon ads Enable full ADS …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly… - …, 2023 - nantes-universite.hal.science
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly, C Roth… - iScience, 2023 - hal.science
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly, C Roth… - iScience, 2023 - hal.umontpellier.fr
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly… - …, 2023 - hal.sorbonne-universite.fr
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
C Chauvin, L Levillayer, M Roumier, H Nielly… - …, 2023 - hal-emse.ccsd.cnrs.fr
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …
patients has proven its efficacy at the clinical level, there is little evidence supporting the …